Acta NaturaeActa NaturaeActa Naturae2075-8251Acta Naturae Ltd2780810.32607/actanaturae.27808Research ArticlesЭкспериментальные статьиResearch ArticleThe potential of the peptide drug Semax and Its derivative for correcting pathological impairments in the animal model of Alzheimer’s diseaseИсследование потенциала пептидного препарата Cемакс и его производного для коррекции патологических нарушений в животной модели болезни АльцгеймераRadchenkoAlexandra I.РадченкоАлександра Игоревна
Russian Federation
sandrinkaradchenko@gmail.comKuzubovaElena V.КузубоваЕлена Валерьевна
Russian Federation
1015artek1015@mail.comApostolAlina A.АпостолАлина Александровна
Russian Federation
alinakum835@gmail.comMitkevichVladimir A.МитькевичВладимир Александрович
Russian Federation
mitkevich@gmail.comAndreevaLiudmila A.АндрееваЛюдмила Александровна
Russian Federation
andr-la.img@yandex.ruLimborskayaSvetlana A.ЛимборскаяСветлана Андреевна
Russian Federation
limbor.img@yandex.ruStepenkoYu. V.СтепенкоЮлия Владимировна
Russian Federation
stepenko@bsu.edu.ruShmigerovaVeronika S.ШмигереваВероника Сергеевна
Russian Federation
belyaeva_v@bsuedu.ruSolinAlexei V.СолинАлексей Владимирович
Russian Federation
solin@bsuedu.ruKorokinMikhail V.КорокинМихаил Викторович
Russian Federation
mkorokin@mail.ruPokrovskiiMikhail V.ПокровскийМихаил Владимирович
Russian Federation
pokrovskii@bsuedu.ruMyasoedovNikolai F.МясоедовНиколай Федорович
Russian Federation
Myasoedov-NF.img@yandex.ruMakarovAlexander A.МакаровАлександр Александрович
Russian Federation
aamakarov@eimb.ruBelgorod State National Research UniversityФГАОУ ВО «Белгородский государственный национальный исследовательский университет»Engelhardt Institute of Molecular Biology, Russian Academy of SciencesФГБУН Институт молекулярной биологии имени В.А. Энгельгардта РАНNational Research Center “Kurchatov Institute”ФГБУ Национальный исследовательский центр «Курчатовский институт»041220251741101200309202529092025Copyright ©; 2025, Radchenko A.I., Kuzubova E.V., Apostol A.A., Mitkevich V.A., Andreeva L.A., Limborskaya S.A., Stepenko Y.V., Shmigerova V.S., Solin A.V., Korokin M.V., Pokrovskii M.V., Myasoedov N.F., Makarov A.A.Copyright ©; 2025, Радченко А.И., Кузубова Е.В., Апостол А.А., Митькевич В.А., Андреева Л.А., Лимборская С.А., Степенко Ю.В., Шмигерева В.С., Солин А.В., Корокин М.В., Покровский М.В., Мясоедов Н.Ф., Макаров А.А.2025Radchenko A.I., Kuzubova E.V., Apostol A.A., Mitkevich V.A., Andreeva L.A., Limborskaya S.A., Stepenko Y.V., Shmigerova V.S., Solin A.V., Korokin M.V., Pokrovskii M.V., Myasoedov N.F., Makarov A.A.Радченко А.И., Кузубова Е.В., Апостол А.А., Митькевич В.А., Андреева Л.А., Лимборская С.А., Степенко Ю.В., Шмигерева В.С., Солин А.В., Корокин М.В., Покровский М.В., Мясоедов Н.Ф., Макаров А.А.https://creativecommons.org/licenses/by/4.0https://actanaturae.ru/2075-8251/article/view/27808

Alzheimer’s disease, first described over a century ago, is currently among the most common neurodegenerative diseases whose significance is increasingly growing with the aging of populations. Throughout the entire period of its study, no remedies have been found that would be effective in treating – or at least significantly slowing – the pathological process, while being sufficiently safe. In this regard, significant attention is paid to the development and application of natural peptide drugs lacking side effects. The present study assessed the effect of the known neuroprotective peptide Semax and its derivative on the behavioral characteristics and development of amyloidosis in transgenic APPswe/PS1dE9/Blg mice acting as a model of Alzheimer’s disease. The open field, novel object recognition, and Barnes maze tests demonstrated that both Semax and its derivative improved cognitive functions in mice. Histological examination showed that these peptides reduced the number of amyloid inclusions in the cortex and hippocampus of the animals’ brains. These findings demonstrate the high potential of Semax and its derivatives when used to develop therapeutic and corrective strategies for Alzheimer’s disease.

Болезнь Альцгеймера – одно из самых распространенных нейродегенеративных заболеваний настоящего времени, значимость которого все более возрастает по мере старения населения, была описана более 100 лет назад. За все время ее изучения не удалось подобрать средства, которые были терапевтически эффективными или существенно замедляли патологический процесс, будучи при этом достаточно безопасными. В этой связи значительное внимание обращено на разработку и применение пептидных препаратов, имеющих природное происхождение и не вызывающих побочных эффектов. В настоящей работе определено действие известного нейропротективного пептида Семакс и его производного на поведенческие характеристики и развитие амилоидоза у трансгенных мышей линии APPswe/PS1dE9/Blg, являющихся моделью болезни Альцгеймера. C использованием тестов «Открытое поле», «Распознавание нового объекта» и «Лабиринт Барнса» обнаружено улучшение когнитивных функций у мышей под действием как Семакса, так и его производного. Гистологическое исследование показало, что данные пептиды снижают число амилоидных включений в коре и гиппокампе головного мозга животных. Полученные результаты показывают перспективность использования Семакса и его производных для разработки методов лечения и коррекции болезни Альцгеймера.

Alzheimer’s diseasepeptide drugbehavioral testinghistological analysisamyloidosisболезнь Альцгеймерапептидный препаратповеденческое тестированиегистологический анализамилоидозРоссийский научный фондRussian Science Foundation19-74-30007Правительство РФGovernment of RFScheltens P, Blennow K, Breteler MMB, et al. Alzheimer’s Disease. Lancet. 2016;388(10043):505-517. doi: 10.1016/S0140-6736(15)01124-1Scheltens P, Blennow K, Breteler MMB, et al. Alzheimer’s Disease. Lancet. 2016;388:505-517. doi: 10.1016/S0140-6736(15)01124-1Kuhla A, Rühlmann C, Lindner T, et al. APPswe/PS1dE9 mice with cortical amyloid pathology show a reduced NAA/Cr ratio without apparent brain atrophy: A MRS and MRI study. NeuroImage Clin. 2017;15:581-586. doi: 10.1016/j.nicl.2017.06.009Kuhla A, Ruhlmann C, Lindner T, et al. APPswe/PS1dE9 mice with cortical amyloid pathology show a reduced NAA/Cr ratio without apparent brain atrophy: A MRS and MRI study. NeuroImage Clinical. 2017;15:581-586. doi:10.1016/j.nicl.2017.06.009Konttinen H, Cabral-da-Silva MEC, Ohtonen S, et al. PSEN1ΔE9, APPswe, and APOE4 Confer Disparate Phenotypes in Human iPSC-Derived Microglia. Stem Cell Reports. 2019;13(4):669-683. doi: 10.1016/j.stemcr.2019.08.004Koroleva SV, Myasoedov NF. Semax As a Universal Drug for Therapy and Research. Biology Bulletin. 2018;45(6):589-600. doi: 10.1134/S1062359018060055Koroleva SV, Myasoedov NF. Semax – Universal Drug for Therapy and Research. Biology Bulletin. 2018;45(6):589-600. doi: 10.1134/S000233291806005X. EDN: BDOQJJCummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer’s disease drug development pipeline: 2019. Alzheimers Dement (N Y). 2019;5:272-293. doi: 10.1016/j.trci.2019.05.008Cummings J, Lee G, Ritter A, et al. Alzheimer’s disease drug development pipeline: 2019. Transl Res Clin Interv. 2019;5:272-293. doi: 10.1016/j.trci.2019.05.008Bairamova SP, Petelin DS, Akhapkin RV, et al. The endogenic neurosteroid system and its role in the pathogenesis and therapy of mental disorders. Res Results Pharmacol. 2023; 9(1):61-69. doi: 10.18413/rrpharmacology.9.10015Bairamova SP, Petelin DS, Akhapkin RV, Kudryashov NV, Sorokina OY, Semin SA, Panfilova V, Volel BA. The endogenic neurosteroid system and its role in the pathogenesis and therapy of mental disorders. Research Results in Pharmacology. 2023;9(1):61-69. doi.org/10.18413/rrpharmacology.9.10015Khan S, Barve KH, Kumar MS. Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease. Curr Neuropharmacol. 2020;18(11):1106-1125. doi: 10.2174/1570159X18666200528142429Khan S, Barve KH, Kumar MS. Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease. Curr Neuropharmacol. 2020;18(11):1106-1125. doi:10.2174/1570159X18666200528142429Stepenko YV, Shmigerova VS, Kostina DA, et al. Study of the neuroprotective properties of the heteroreceptor EPOR/CD131 agonist of peptide structure in tau-proteinopathy modeling. Res Results Pharmacol. 2024;10(2) 41-47. doi: 10.18413/rrpharmacology.10.492Stepenko YV, Shmigerova VS, Kostina DA, Shcheblykina OV, Zhernakova NI, Solin AV, Koroleva NV, Markovskaya VA, Dudnikova OV, Bolgov AA. Study of the neuroprotective properties of the heteroreceptor EPOR/CD131 agonist of peptide structure in tau-proteinopathy modeling. Research Results in Pharmacology. 2024;10(2)41-47. doi: 10.18413/rrpharmacology.10.492Platt B, Drever B, Koss D, et al. Abnormal cognition, sleep, EEG and brain metabolism in a novel knock-in Alzheimer mouse, PLB1. PLoS One. 2011;6(11):e27068. doi: 10.1371/journal.pone.0027068Platt B, Drever B, Koss D, et al. Abnormal cognition, sleep, EEG and brain metabolism in a novel knock-in Alzheimer mouse, PLB1. PLoS. 2011;6:e27068. doi: 10.1371/journal.pone.0027068Lysikova EA, Kukharsky MS, Chaprov KD, et al. Behavioural impairments in mice of a novel FUS transgenic line recapitulate features of frontotemporal lobar degeneration. Genes Brain Behav. 2019;18(8):e12607. doi: 10.1111/gbb.12607Lysikova EA, Kukharsky MS, Chaprov KD, et al. Behavioural impairments in mice of a novel FUS transgenic line recapitulate features of frontotemporal lobar degeneration. Genes Brain and Behavior. 2019;18:e12607. doi: 10.1111/gbb.12607Forest KH, Alfulaij N, Arora K, et al. Protection against β-amyloid neurotoxicity by a non-toxic endogenous N-terminal β-amyloid fragment and its active hexapeptide core sequence. J Neurochem. 2018;144(2):201-217. doi: 10.1111/jnc.14257Forest KH, Alfulaij N, Arora K, Taketa R, Sherrin T, Todorovic C, Lawrence JLM, Yoshikawa GT, Ng HL, Hruby VJ, Nichols RA. Protection against β-amyloid neurotoxicity by a non-toxic endogenous N-terminal β-amyloid fragment and its active hexapeptide core sequence. J Neurochem. 2018;144(2):201-217. doi: 10.1111/jnc.14257Kozin SA, Barykin EP, Mitkevich VA, Makarov AA. Anti-amyloid therapy of Alzheimer’s disease: Current state and prospects. Biochemistry (Mosc). 2018;83(9):1057-1067. doi: 10.1134/S0006297918090079Kozin SA, Barykin EP, Mitkevich VA, et al. Anti-amyloid therapy of Alzheimer’s disease: Current state and prospects. Biochem. Mosc. 2018;83:1057-1067. doi: 10.1134/S0006297918090079Istrate AN, Tsvetkov PO, Mantsyzov AB, et al. NMR solution structure of rat aβ(1-16): toward understanding the mechanism of rats’ resistance to Alzheimer’s disease. Biophys J. 2012;102(1):136-143. doi: 10.1016/j.bpj.2011.11.4006Cummings J, Fox N. Defining Disease Modifying Therapy for Alzheimer’s Disease. J Prev Alzheimers Dis. 2017;4(2):109-115. doi: 10.14283/jpad.2017.12Cummings J, Fox N. Defining Disease Modifying Therapy for Alzheimer’s Disease. J Prev Alzheimer’s Dis. 2017;4(2):109-115. doi: 10.14283/jpad.2017.12Sengupta U, Nilson AN, Kayed R. The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy. EBioMedicine. 2016;6:42-49. doi: 10.1016/j.ebiom.2016.03.035Sengupta A, Nilson N, Kayed R. The Role of Amyloid-β Oligomers in Toxicity, Propagation, and Immunotherapy. EBioMedicine. 2016;6:42-49. doi: 10.1016/j.ebiom.2016.03.035Lysikova EA, Kuzubova EV, Radchenko AI, et al. APPswe/PS1dE9/Blg Transgenic Mouse Line for Modeling Cerebral Amyloid Angiopathy in Alzheimer’s Disease. Mol Biol (Mosс). 2023;57(1):85-94. doi: 10.31857/S0026898423010081Lysikova EA, Kuzubova EV, Radchenko AI, Patrakhanov EA, Chaprov KD, Korokin MV, Deykin AV, Gudyrev OS, Pokrovskii MV. APPswe/PS1dE9/Blg Transgenic Mouse Line for Modeling Cerebral Amyloid Angiopathy in Alzheimer’s Disease. Mol Biol (Mosk.). 2023;57(1):85-94. doi: 10.31857/S0026898423010081. EDN: AXGEVNAshmarin IP, Nezaviba’tko VN, Myasoedov NF, et al. A nootropic adrenocorticotropin analog 4-10-semax (15 years experience in its design and study). Zh Vyssh Nerv Deiat Im I P Pavlova. 1997;47(2):420-430Ashmarin IP, Nezavibatko VN, Myasoedov NF, Kamensky AA, Grivennikov IA, Ponomareva-Stepnaya MA, Andreeva LA, Kaplan AY, Koshelev VB, Ryasina TV. Nootropic analogue of adrenocorticotropin 4-10 Semax (The experience of desing and investigation over 15 years). Neuroscience and Behavioral Physiology. 1997;47(2):420-430. EDN: MOXKPPMyasoedov NF, Grivennikov IA. Neuropeptides and their analogues in the regulation of the functions of the mammalian nervous system, including humans. From the synthesis and study of their mechanisms of action to the creation of new generation medicines. In: Problemy i perspektivy molekulyarnoi genetiki [Problems and prospects of molecular genetics]. Moscow: Nauka; 2004.2:195–236.Мясоедов НФ, Гривенников ИА. Нейропептиды и их аналоги в регуляции функций нервной системы млекопитающих, включая человека. От синтеза и изучения механизмов их действия до создания лекарственных средств нового поколения. Проблемы и перспективы молекулярной генетики. М.: Наука. 2004;2:195–236.Potaman VN, Antonova LV, Dubynin VA, et al. Entry of the synthetic ACTH(4–10) analogue into the rat brain following intravenous injection. Neurosci Lett. 1991;127(1):133-136. doi: 10.1016/0304-3940(91)90912-dPotaman VN, Antonova LV, Dubynin VA, Zaitzev DA, Kamensky AA, Myasoedov NF, Nezavibatko VN. Entry of the synthetic ACTH(4–10) analogue into the rat brain following intravenous injection. Neurosci Lett. 1991;127:133-136. doi.org/10.1016/0304-3940(91)90912-dPonomareva-Stepnaia MA, Bakharev VD, Nezavibatko VN, Andreeva LA, Alfeeva LYu, Potaman VN. Sravnitelnye issledovaniia analogov AKTG(4–10) stimulatorov obucheniia i pamiati. Khimiko-farmatsevticheskii zhurnal. 1986;20(6):667–670.Пономарева-Степная МА, Бахарев ВД, Незавибатько ВН, Андреева ЛА, Алфеева ЛЮ, Потаман ВН. Сравнительные исследования аналогов АКТГ(4–10) стимуляторов обучения и памяти. Хим.-фарм. ж. 1986;20(6):667-670.Levitskaya NG, Glazova NYu, Sebentsova EA, et al. Investigation of the Spectrum of Physiological Activities of the Heptapeptide Semax, an ACTH 4–10 Analogue. Neurochemical J. 2008;2(1–2):95-101. doi: 10.1134/S1819712408010182Levitskaya NG, Glazova NYu, Sebentsova EA, Andreeva LA, Myasoedov NF, Manchenko DM, Vilensky DA, Kamensky AA. Investigation of the Spectrum of Physiological Activities of the Heptapeptide Semax, an ACTH 4–10 Analogue. Neurochemical J. 2008;2(1-2):95-101. doi:10.1134/S1819712408010182. EDN: LLKPDTLevitskaya NG, Sebentsova EA, Glazova NYu, et al. Study on the neurotropic activity of the products of Semax enzymatic degradation. Dokl Biol Sci 2000;372:243-246Levitskaya NG, Sebentsova EA, Glazova NYu, Voskresenskaya OG, Andreeva LA, Alfeeva LYu, Kamenskii AA, Myasoedov NF. Study on the neurotropic activity of the products of Semax enzymatic degradation. Dokl. Biol. Sci. 2000;372(1-6):243-246. EDN: CDIQZAMjasoedov NF, Gavrilova SI, Kalyn JaB, et al, inventors; Federal Service for Intellectual Property, assignee. Agent and method for prevention and treatment of the patients with Alzheimer’s disease. Russian Federation patent RUS 2384343. March 20, 2010.Patent RUS № 2384343/20.03.2010. Byul. № 8. Mjasoedov NF, Gavrilova SI, Kalyn JaB, Kolykhalov IV, Mikhajlova NM, Selezneva ND, Sokolova ON, Tiganov AS, Andreeva LA. Agent and method for prevention and treatment of the patients with Alzheimer’s disease. EDN: UQIOJWIlina АR, Popovich IG, Ryzhak GА, Khavinson VKh. Prospects for use of short peptides in pharmacotherapeutic correction of Alzheimer’s disease. Adv Geront. 2024:37(1-2):10-20. doi: 10.34922/AE.2024.37.1-2.001Ilina АR, Popovich IG, Ryzhak GА, Khavinson VKh. Prospects for use of short peptides in pharmacotherapeutic correction of Alzheimer’s disease. Adv Geront. 2024:37(1-2):10-20. doi: 10.34922/AE.2024.37.1-2.001. EDN: SPXNEDPonomareva-Stepnaia MA, Nezavibatko VN, Antonova LV, et al. Analog ACTG(4–10) stimulator obucheniia prolongirovannogo deistviia. Khimiko-farmatsevticheskii zhurnal. 1984;18(7):790-795.Пономарева-Степная МА, Незавибатько ВН, Антонова ЛВ, Андреева ЛА, Алфеева ЛЮ, Потаман ВН, Каменский АА, Ашмарин ИП. Аналог АКТГ(4–10) стимулятор обучения пролонгированного действия. Хим.- фарм. ж. 1984;18(7):790-795.Ryzhak GА, Ilina АR. Prospects of using peptide drugs for the prevention and treatment of Alzheimer’s disease. Problems of Geroscience. 2024;4:223-226. doi: 10.37586/2949-4745-4-2024-223-226Ryzhak GА, Ilina АR. Prospects of using peptide drugs for the prevention and treatment of Alzheimer’s disease. Problems of Geroscience. 2024;4(8):223-226. doi: 10.37586/2949-4745-4-2024-223-226. EDN: RCJZKFVyunova TV, Andreeva LA, Shevchenko KV, Myasoedov NF. An integrated approach to study the molecular aspects of regulatory peptides biological mechanism. J Labelled Comp Radiopharm. 2019;62(12):812-822. doi: 10.1002/jlcr.3785Vyunova TV, Andreeva LA, Shevchenko KV, Myasoedov NF. An integrated approach to study the molecular aspects of regulatory peptides biological mechanism. J Labelled Comp Radiopharm. 2019;62(12):812-822. doi.org/10.1002/jlcr.3785Kozin SA, Makarov AA. The convergence of Alzheimer’s disease pathogenesis concepts. Mol Biol (Mosk). 2019;53(6):1020-1028. doi: 10.1134/S0026898419060107Kozin SA, Makarov AA. The convergence of Alzheimer’s disease pathogenesis concepts. Mol Biol. (Moscow). 2019;53(6):1020-1028. doi: 10.1134/S0026898419060107. EDN: JAYLXHBarykin EP, Garifulina AI, Kruykova EV, et al. Isomerization of Asp7 in Beta-Amyloid Enhances Inhibition of the alpha7 Nicotinic Receptor and Promotes Neurotoxicity. Cells. 2019;8(8):771-787. doi: 10.3390/cells8080771Barykin EP, Garifulina AI, Kruykova EV, Spirova EN, Anashkina AA, Adzhubei AA, Shelukhina IV, Kasheverov IE, Mitkevich VA, Kozin SA, Hollmann M, Tsetlin VI, Makarov AA. Isomerization of Asp7 in Beta-Amyloid Enhances Inhibition of the alpha7 Nicotinic Receptor and Promotes Neurotoxicity. Cells. 2019;8(8):771-787. doi: 10.3390/cells8080771